Impact of Dapagliflozin on Left ventricular hemodynamics and Exercise-induced Pulmonary hypertension evaluated by echocardiography in patients with type 2 diabetes; an open-label prospective randomized controlled trial - Impact of Dapagliflozin on Left ventricular hemodynamics and Exercise-induced Pulmonary hypertension evaluated by echocardiography in patients with type 2 diabetes; an open-label prospective randomized controlled trial (IDOL-EPOC Study )

The Japan Society for Patient Reported Outcome0 个研究点目标入组 78 人开始时间: 2016年8月30日最近更新: 2023年10月17日

试验速览

暂无简介。

•Patients who fall into one or more of the following criteria are excluded from participating in the study. 1. Patients requiring a legally acceptable representative 2. Patients with type 1 diabetes 3. Patients who have received an SGLT2 inhibitor, subcutaneous injection of insulin, or subcutaneous injection of glucagon-like-peptide-1 agonist within 12 weeks before consenting to study participation 4. Patients with the stage-III hypertension (early morning systolic blood pressure measured at home is 175 mmHg or higher, or systolic blood pressure measured at office is 180 mmHg or higher) 5. Patients with chronic respiratory disease that needs medical treatment 6. Patients with pulmonary hypertension 7. Patients with severe renal failure (GFR is below 45 mL/min/1.73 m2) 8. Patients with an infectious disease or undergoing cancer treatment 9. Patients who have undergone surgery or catheter treatment within a year before consenting to study participation 10. Patients who are or may be pregnant 11. Patients who are drug addicted or alcohol dependent 12. Patients with NYHA III-IV heart failure 13. Patients considered inappropriate by their attending investigators

发起方

The Japan Society for Patient Reported Outcome